Latest studies
- Completed
Antiretroviral research for Watoto
This study looks at the best ways to give and monitor anti-HIV medicines in children and young people. Researchers want to see whether regular clinic check-ups are as effective as routine blood tests, and whether starting with extra medicines before switching to a standard routine works well.
Human immunodeficiency virusUganda - CompletedPhase II/III
Comparing a two-drug fixed dose combination containing dolutegravir and lamivudine to the usual three-drug combination for maintenance treatment in children aged 2-14 years with HIV infection living in Europe, Thailand and Africa
This trial looks at whether a simpler two-in-one daily tablet works just as well as standard three-drug treatments for children aged 2 to 14 living with HIV. Researchers want to see if taking fewer medicines keeps HIV controlled while causing fewer side effects as children grow.
HIV infection in childrenUganda - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
Locally Advanced or Metastatic Breast CancerUganda - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
Hepatocellular CarcinomaUganda - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerUganda - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerUganda - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaUganda - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerUganda - RecruitingPHASE3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study looks at a new medicine called etavopivat for people with sickle cell disease. It aims to see if it reduces painful crises, organ damage, and tiredness, and improves exercise. Participants will get either the medicine or a dummy pill.
Sickle Cell DiseaseUganda - Recruiting
An International Observational Study of Adults With Acute Infection
This study looks at adults admitted to hospital with infections. Researchers will collect information and samples to better understand different types of infections, how they affect people, and how best to treat them. This helps plan future studies and improve care.
Infectious DiseaseUganda - Active not recruiting
Improving Infant Hydrocephalus Outcomes in Uganda
This study in Uganda looks at a new way to treat hydrocephalus, a condition where fluid builds up in a baby's brain. It compares a traditional shunt with a different surgery (ETV/CPC) to see if it works better for young babies, helping them avoid lifelong shunt problems.
HydrocephalusUganda - Active not recruitingPHASE2, PHASE3
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
This study looks at a two-drug treatment (Dolutegravir and Lamivudine) for children and young people with HIV, aged 2 to 15. It aims to see if it's as safe and effective as their current three-drug therapy.
HIV InfectionsUganda - Active not recruitingPHASE2, PHASE3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
This study looks at new ways to treat HIV in children. It's testing if certain medicines (ATV/co, DRV/co, F/TAF) are safe and work well for children aged 4 weeks to 17 years. The goal is to find better treatment options for young people living with HIV.
Acquired Immune Deficiency Syndrome (AIDS)HIV InfectionsUganda - RecruitingPHASE3
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
This study is testing a new treatment called anti-COVID-19 immunoglobulin (hIVIG) for adults recently diagnosed with COVID-19 who don't need hospital care. Researchers want to see if hIVIG is safe and effective in preventing severe illness compared to a dummy treatment (placebo).
COVIDSARS-CoV2 InfectionCovid19Uganda